However, epidemiological analyses have shown that T2DM patients under glycemic control, in particular, those who use insulin analogs, have at least a 30% higher risk for developing cancer in breast, colon, prostate, kidney and pancreas tissues. This evidence concerns the gene INS and type 2 diabetes mellitus.